Phio Pharmaceuticals Corp [NASDAQ: PHIO] plunged by -$0.19 during the normal trading session on Monday and reaching a high of $4.1899 during the day while it closed the day at $1.86.
Phio Pharmaceuticals Corp stock has also loss -13.97% of its value over the past 7 days. However, PHIO stock has declined by -20.85% in the 3 months of the year. Over the past six months meanwhile, it has lost -1.06% and lost -40.95% year-on date.
The market cap for PHIO stock reached $10.65 million, with 5.73 million shares outstanding and 4.86 million shares in the current float. Compared to the average trading volume of 126.58K shares, PHIO reached a trading volume of 161567357 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Phio Pharmaceuticals Corp [PHIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PHIO shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PHIO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Phio Pharmaceuticals Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 05, 2020, representing the official price target for Phio Pharmaceuticals Corp stock.
The Price to Book ratio for the last quarter was 0.88, with the Price to Cash per share for the same quarter was set at 1.88.
PHIO stock trade performance evaluation
Phio Pharmaceuticals Corp [PHIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.97. With this latest performance, PHIO shares dropped by -22.18% in over the last four-week period, additionally sinking by -1.06% over the last 6 months – not to mention a rise of 3.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PHIO stock in for the last two-week period is set at 29.33, with the RSI for the last a single of trading hit 0.36, and the three-weeks RSI is set at 0.23 for Phio Pharmaceuticals Corp [PHIO]. The present Moving Average for the last 50 days of trading for this stock 2.18, while it was recorded at 2.04 for the last single week of trading, and 2.04 for the last 200 days.
Phio Pharmaceuticals Corp (PHIO) Capital Structure & Debt Analysis
According to recent financial data for Phio Pharmaceuticals Corp. ( PHIO), the Return on Equity (ROE) stands at -102.18%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -85.38%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Phio Pharmaceuticals Corp’s Return on Invested Capital (ROIC) is -70.18%, showcasing its effectiveness in deploying capital for earnings.
Phio Pharmaceuticals Corp (PHIO) Efficiency & Liquidity Metrics
Based on Phio Pharmaceuticals Corp’s (PHIO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Phio Pharmaceuticals Corp (PHIO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Phio Pharmaceuticals Corp. (PHIO) effectively leverages its workforce, generating an average of -$1416000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.36% and a Quick Ratio of 9.36%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Phio Pharmaceuticals Corp [PHIO] stock
With the latest financial reports released by the company, Phio Pharmaceuticals Corp posted -1.54/share EPS, while the average EPS was predicted by analysts to be reported at -4.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PHIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Phio Pharmaceuticals Corp go to 64.39%.
Phio Pharmaceuticals Corp [PHIO]: Institutional Ownership
There are presently around $10.24%, or 11.08%% of PHIO stock, in the hands of institutional investors.
